|
US20030114410A1
(en)
|
2000-08-08 |
2003-06-19 |
Technion Research And Development Foundation Ltd. |
Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
|
|
GB0521139D0
(en)
*
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
ES2544888T3
(es)
|
2006-06-08 |
2015-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Prevención o remedio para enfermedades inflamatorias
|
|
CA2693310C
(en)
|
2007-08-02 |
2018-11-27 |
Arresto Biosciences, Inc. |
Lox and loxl2 inhibitors, antibodies and uses thereof
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
CA2708065C
(en)
|
2007-12-05 |
2015-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for pruritus
|
|
TWI548418B
(zh)
|
2007-12-05 |
2016-09-11 |
中外製藥股份有限公司 |
Anti-NR10 / IL-31RA antibody and its use
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
EP2282769A4
(en)
*
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
KR20110016959A
(ko)
*
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US8822645B2
(en)
*
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
KR20160062207A
(ko)
*
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항ｎｒ１０ 항체 및 그의 이용
|
|
JO3382B1
(ar)
*
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
US9107935B2
(en)
|
2009-01-06 |
2015-08-18 |
Gilead Biologics, Inc. |
Chemotherapeutic methods and compositions
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
中外製藥股份有限公司 |
Antibody constant region change body
|
|
BRPI1012195A2
(en)
*
|
2009-05-01 |
2018-04-24 |
Abbott Laboratories |
double variable domain immunoglobulins and their uses
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2771702A1
(en)
|
2009-08-21 |
2011-02-24 |
Gilead Biologics, Inc. |
Catalytic domains from lysyl oxidase and loxl2
|
|
AR078651A1
(es)
*
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
US9790280B2
(en)
|
2011-10-26 |
2017-10-17 |
Elanco Tiergesundheit Ag |
Monoclonal canine CD20 antibodies and methods of use
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
US10379127B2
(en)
|
2013-11-27 |
2019-08-13 |
Welcome Receptor Antibodies Pty Ltd |
Marker of cell death
|
|
UY36302A
(es)
|
2014-09-15 |
2016-04-29 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
FI3284480T3
(fi)
|
2015-04-14 |
2025-09-11 |
Chugai Pharmaceutical Co Ltd |
IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
|
|
TWI728953B
(zh)
|
2015-04-24 |
2021-06-01 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
EP4060344A1
(en)
|
2015-06-08 |
2022-09-21 |
Arquer Diagnostics Limited |
Methods and kits
|
|
GB201509907D0
(en)
*
|
2015-06-08 |
2015-07-22 |
Urosens Ltd |
Antibodies
|
|
EP3304082B1
(en)
|
2015-06-08 |
2020-05-13 |
Arquer Diagnostics Limited |
Methods for analysing a urine sample
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
EP3454864A4
(en)
*
|
2016-04-21 |
2021-01-13 |
Abbvie Stemcentrx LLC |
Novel anti-bmpr1b antibodies and methods of use
|
|
GB201707938D0
(en)
|
2017-05-17 |
2017-06-28 |
Univ Sheffield |
Compounds
|
|
SG11202009629YA
(en)
|
2018-04-02 |
2020-10-29 |
Amgen Inc |
Erenumab compositions and uses thereof
|
|
US12156918B2
(en)
|
2018-10-08 |
2024-12-03 |
The Uab Research Foundation |
Neuroendocrine cancer targeted therapy
|
|
GB201818649D0
(en)
|
2018-11-15 |
2019-01-02 |
Univ Sheffield |
Compounds
|
|
GB201818651D0
(en)
|
2018-11-15 |
2019-01-02 |
Univ Sheffield |
Compounds
|
|
WO2021100794A1
(ja)
|
2019-11-20 |
2021-05-27 |
中外製薬株式会社 |
抗体含有製剤
|
|
CN113512109B
(zh)
*
|
2021-03-09 |
2022-03-25 |
北京康乐卫士生物技术股份有限公司 |
一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用
|
|
US20260174823A1
(en)
*
|
2022-11-10 |
2026-06-25 |
The Children's Medical Center Corporation |
Cgrp/ramp1 blockade to treat endometriosis-associated pain and reduce endometriosis lesions
|
|
GB202303531D0
(en)
*
|
2023-03-10 |
2023-04-26 |
Fusion Antibodies Plc |
Antibodies and uses thereof
|
|
WO2026052977A1
(en)
*
|
2024-09-09 |
2026-03-12 |
Finn Therapeutics Ltd. |
Antibodies binding receptor activity-modifying protein (ramp)-3 and uses thereof
|